Immunotherapy in the treatment of non-small cell lung cancer

Raghav Sundar, Richie Soong, Byoung Chul Cho, Julie R. Brahmer, Ross A. Soo

Research output: Contribution to journalReview articlepeer-review

92 Scopus citations


Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.

Original languageEnglish (US)
Pages (from-to)101-109
Number of pages9
JournalLung Cancer
Issue number2
StatePublished - Aug 2014


  • CTLA-4
  • Immunotherapy
  • Ipilimumab
  • Nivolumab
  • Non-small cell lung cancer
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Immunotherapy in the treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this